Hepatitis C News

AMSTERDAM — When adjusted for age and severity of liver disease, occurrence and recurrence of hepatocellular carcinoma after curing hepatitis C virus showed no difference between treatment with interferon or direct-acting antivirals, according to an expert at the International Liver Congress.

As we continue to see the success of direct-acting antiviral therapy in treating hepatitis C virus, we must be aware of any potential complications from the underlying liver disease after successful treatment, especially hepatocellular carcinoma.

The FDA has approved sofosbuvir and ledipasvir/sofosbuvir as supplemental applications for the treatment of hepatitis C in children aged 12 to 17 years, according to an FDA news release.

AMSTERDAM — While hepatitis C virus-positive liver donation into HCV-positive recipients solves a number of public health problems, donation into HCV-negative recipients remains controversial, according to a presenter at the International Liver Congress.

AMSTERDAM — The benefits of both double and triple direct-acting antiviral therapy combinations depend on myriad patient and disease factors, according to findings presented at the International Liver Congress.

AMSTERDAM — In this exclusive video from International Liver Congress, Jason Grebely, PhD, from the Kirby Institute at the University of New South Wales, Sydney, reviews strategies discussed at the conference for enhancing prevention and treatment of hepatitis C among people who inject drugs.

AMSTERDAM — Dealing with hepatitis C virus as a systemic disease, and not just a complication of the liver, may aid clinicians in reducing extrahepatic manifestations of the infection, according to experts at the International Liver Congress.

Hepatitis C incidence among HIV-positive men who have sex with men has shown no significant decline in Europe, though the trends differ by geographical region and age, according to results of a recently published study.

Direct-acting antiviral therapy for hepatitis C was highly effective and well-tolerated in patients aged 65 years and older, resulting in most patients achieving sustained virologic response, according to results of a recent study.

The vast majority of young people with hepatitis C virus infection in the United States live more than 10 miles away from a syringe services program, researchers said.